Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.

Cancer Med · 2024 · PMC11259557 · PMID 39031941

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

With the increase in drug dose, AUC and C max also showed an increasing trend, and the increase ratio was linear with the dose increase ratio.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.